Kyntra Bio (KYNB)
NASDAQ:KYNB
Want to see KYNB full AI Analyst Report?
Earnings Data
Report Date
Aug 10, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-3.27Last Year’s EPS
-1.88Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress across two key programs (FG-3246/FG-3180 and roxadustat), supportive subgroup efficacy data, validated mitigation of a key ADC safety issue, improved financial discipline with reduced R&D and SG&A, revenue growth, and a cash runway into 2028. Key risks include ongoing net losses, small revenue base, an unresolved biomarker statistical significance that 'just missed' in the IST, residual safety concerns around neutropenia, and reliance on upcoming binary clinical readouts and enrollment execution. On balance, the positives (clinical signals, validated mitigation strategy, constructive FDA feedback on roxadustat, cash runway and expense reductions) outweigh the lowlights, though the company remains dependent on near-term trial execution.Company Guidance
Revenue Growth
Total revenue of $3.7M in Q1 2026 vs $2.7M in Q1 2025, an increase of approximately 37% year-over-year.
Improved Loss and Expense Control
Net loss from continuing operations improved to $15.1M (-$3.74 per share) from $16.8M (-$4.15) a year ago, a ~10% reduction in net loss. Total operating costs were essentially flat at $17.6M vs $17.7M prior year; R&D decreased ~17% to $7.6M and SG&A decreased ~27% to $5.9M.
Strong Cash Position and Runway
Cash, cash equivalents, investments and accounts receivable totaled $100.3M as of March 31, 2026, with management expecting a cash runway into 2028 to fund U.S. pipeline activities.
FG-3246 Phase I Monotherapy Efficacy Signal
Phase I monotherapy topline: median rPFS of 8.7 months in heavily pretreated mCRPC patients; PSA reductions >50% in 36% of patients; overall response rate (ORR) 20% of evaluable patients with median duration of response 7.5 months. All ORRs observed at the 2.7 mg/kg dose, suggesting a dose response.
Encouraging Combination Data (FG-3246 + Enzalutamide)
Investigator-initiated study (n=44) showed median rPFS of 7.0 months in an all-comer cohort and a clinically notable 10.1 months median rPFS in patients who had progressed on only 1 prior ARPI; PSA50 response 40% in that subgroup.
CD46 PET (FG-3180) as a Potential Biomarker
IST data showed higher FG-3180 tumor uptake trended with greater PSA50 response to FG-3246; this represents the first demonstrated association between CD46 expression and response and supports FG-3180 as a potential companion diagnostic to enrich Phase III populations.
Neutropenia Management Strategy Validated
IST showed substantial reduction in grade ≥3 neutropenia when using G-CSF prophylaxis versus Phase I monotherapy, leading to incorporation of primary G-CSF prophylaxis in the ongoing Phase II to reduce dose interruptions and maintain exposure.
Roxadustat Clinical Opportunity and Positive Subgroup Data
Roxadustat received orphan drug designation for lower-risk MDS. Post-hoc MATTERHORN subgroup with high transfusion burden: 36% achieved ≥8-week transfusion independence vs 7% for placebo (nominal p=0.041), supporting targeted Phase III plans.
Clear Development Milestones and Timeline
Active Phase II monotherapy dose-optimization trial for FG-3246 (75 patients) with interim analysis planned in Q4 2026 and mature rPFS data anticipated in 2027; Phase III for roxadustat targeted to initiate in H2 2026.
KYNB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KYNB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 11, 2026 | $6.80 | $7.22 | +6.25% |
Mar 16, 2026 | $7.00 | $7.37 | +5.29% |
Nov 10, 2025 | $11.00 | $9.94 | -9.64% |
Aug 11, 2025 | $8.37 | $9.25 | +10.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kyntra Bio (KYNB) report earnings?
Kyntra Bio (KYNB) is schdueled to report earning on Aug 10, 2026, After Close (Confirmed).
What is Kyntra Bio (KYNB) earnings time?
Kyntra Bio (KYNB) earnings time is at Aug 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KYNB EPS forecast?
KYNB EPS forecast for the fiscal quarter 2026 (Q2) is -3.27.